The global Viral Vector and Plasmid DNA market size is predicted to grow from US$ 927 million in 2025 to US$ 2771 million in 2031; it is expected to grow at a CAGR of 20.0% from 2025 to 2031.
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
The 鈥淰iral Vector and Plasmid DNA Industry Forecast鈥� looks at past sales and reviews total world Viral Vector and Plasmid DNA sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Vector and Plasmid DNA sales for 2025 through 2031. With Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector and Plasmid DNA and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector and Plasmid DNA.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector and Plasmid DNA market by product type, application, key players and key regions and countries.
Segmentation by Type:
Plasmid DNA
Viral Vector
Segmentation by Application:
Cancer
Virus Infection
Hereditary Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Viral Vector and Plasmid DNA Market Size (2020-2031)
2.1.2 Viral Vector and Plasmid DNA Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Viral Vector and Plasmid DNA by Country/Region (2020, 2024 & 2031)
2.2 Viral Vector and Plasmid DNA Segment by Type
2.2.1 Plasmid DNA
2.2.2 Viral Vector
2.3 Viral Vector and Plasmid DNA Market Size by Type
2.3.1 Viral Vector and Plasmid DNA Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Viral Vector and Plasmid DNA Market Size Market Share by Type (2020-2025)
2.4 Viral Vector and Plasmid DNA Segment by Application
2.4.1 Cancer
2.4.2 Virus Infection
2.4.3 Hereditary Disease
2.5 Viral Vector and Plasmid DNA Market Size by Application
2.5.1 Viral Vector and Plasmid DNA Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Viral Vector and Plasmid DNA Market Size Market Share by Application (2020-2025)
3 Viral Vector and Plasmid DNA Market Size by Player
3.1 Viral Vector and Plasmid DNA Market Size Market Share by Player
3.1.1 Global Viral Vector and Plasmid DNA Revenue by Player (2020-2025)
3.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Player (2020-2025)
3.2 Global Viral Vector and Plasmid DNA Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Viral Vector and Plasmid DNA by Region
4.1 Viral Vector and Plasmid DNA Market Size by Region (2020-2025)
4.2 Global Viral Vector and Plasmid DNA Annual Revenue by Country/Region (2020-2025)
4.3 Americas Viral Vector and Plasmid DNA Market Size Growth (2020-2025)
4.4 APAC Viral Vector and Plasmid DNA Market Size Growth (2020-2025)
4.5 Europe Viral Vector and Plasmid DNA Market Size Growth (2020-2025)
4.6 Middle East & Africa Viral Vector and Plasmid DNA Market Size Growth (2020-2025)
5 Americas
5.1 Americas Viral Vector and Plasmid DNA Market Size by Country (2020-2025)
5.2 Americas Viral Vector and Plasmid DNA Market Size by Type (2020-2025)
5.3 Americas Viral Vector and Plasmid DNA Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector and Plasmid DNA Market Size by Region (2020-2025)
6.2 APAC Viral Vector and Plasmid DNA Market Size by Type (2020-2025)
6.3 APAC Viral Vector and Plasmid DNA Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Viral Vector and Plasmid DNA Market Size by Country (2020-2025)
7.2 Europe Viral Vector and Plasmid DNA Market Size by Type (2020-2025)
7.3 Europe Viral Vector and Plasmid DNA Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Viral Vector and Plasmid DNA by Region (2020-2025)
8.2 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Type (2020-2025)
8.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Viral Vector and Plasmid DNA Market Forecast
10.1 Global Viral Vector and Plasmid DNA Forecast by Region (2026-2031)
10.1.1 Global Viral Vector and Plasmid DNA Forecast by Region (2026-2031)
10.1.2 Americas Viral Vector and Plasmid DNA Forecast
10.1.3 APAC Viral Vector and Plasmid DNA Forecast
10.1.4 Europe Viral Vector and Plasmid DNA Forecast
10.1.5 Middle East & Africa Viral Vector and Plasmid DNA Forecast
10.2 Americas Viral Vector and Plasmid DNA Forecast by Country (2026-2031)
10.2.1 United States Market Viral Vector and Plasmid DNA Forecast
10.2.2 Canada Market Viral Vector and Plasmid DNA Forecast
10.2.3 Mexico Market Viral Vector and Plasmid DNA Forecast
10.2.4 Brazil Market Viral Vector and Plasmid DNA Forecast
10.3 APAC Viral Vector and Plasmid DNA Forecast by Region (2026-2031)
10.3.1 China Viral Vector and Plasmid DNA Market Forecast
10.3.2 Japan Market Viral Vector and Plasmid DNA Forecast
10.3.3 Korea Market Viral Vector and Plasmid DNA Forecast
10.3.4 Southeast Asia Market Viral Vector and Plasmid DNA Forecast
10.3.5 India Market Viral Vector and Plasmid DNA Forecast
10.3.6 Australia Market Viral Vector and Plasmid DNA Forecast
10.4 Europe Viral Vector and Plasmid DNA Forecast by Country (2026-2031)
10.4.1 Germany Market Viral Vector and Plasmid DNA Forecast
10.4.2 France Market Viral Vector and Plasmid DNA Forecast
10.4.3 UK Market Viral Vector and Plasmid DNA Forecast
10.4.4 Italy Market Viral Vector and Plasmid DNA Forecast
10.4.5 Russia Market Viral Vector and Plasmid DNA Forecast
10.5 Middle East & Africa Viral Vector and Plasmid DNA Forecast by Region (2026-2031)
10.5.1 Egypt Market Viral Vector and Plasmid DNA Forecast
10.5.2 South Africa Market Viral Vector and Plasmid DNA Forecast
10.5.3 Israel Market Viral Vector and Plasmid DNA Forecast
10.5.4 Turkey Market Viral Vector and Plasmid DNA Forecast
10.6 Global Viral Vector and Plasmid DNA Forecast by Type (2026-2031)
10.7 Global Viral Vector and Plasmid DNA Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Viral Vector and Plasmid DNA Forecast
11 Key Players Analysis
11.1 Brammer Bio
11.1.1 Brammer Bio Company Information
11.1.2 Brammer Bio Viral Vector and Plasmid DNA Product Offered
11.1.3 Brammer Bio Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Brammer Bio Main Business Overview
11.1.5 Brammer Bio Latest Developments
11.2 Oxford BioMedica
11.2.1 Oxford BioMedica Company Information
11.2.2 Oxford BioMedica Viral Vector and Plasmid DNA Product Offered
11.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Oxford BioMedica Main Business Overview
11.2.5 Oxford BioMedica Latest Developments
11.3 Cobra Biologics
11.3.1 Cobra Biologics Company Information
11.3.2 Cobra Biologics Viral Vector and Plasmid DNA Product Offered
11.3.3 Cobra Biologics Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Cobra Biologics Main Business Overview
11.3.5 Cobra Biologics Latest Developments
11.4 FinVector
11.4.1 FinVector Company Information
11.4.2 FinVector Viral Vector and Plasmid DNA Product Offered
11.4.3 FinVector Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 FinVector Main Business Overview
11.4.5 FinVector Latest Developments
11.5 Lonza
11.5.1 Lonza Company Information
11.5.2 Lonza Viral Vector and Plasmid DNA Product Offered
11.5.3 Lonza Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Lonza Main Business Overview
11.5.5 Lonza Latest Developments
11.6 BioReliance
11.6.1 BioReliance Company Information
11.6.2 BioReliance Viral Vector and Plasmid DNA Product Offered
11.6.3 BioReliance Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 BioReliance Main Business Overview
11.6.5 BioReliance Latest Developments
11.7 MolMed
11.7.1 MolMed Company Information
11.7.2 MolMed Viral Vector and Plasmid DNA Product Offered
11.7.3 MolMed Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 MolMed Main Business Overview
11.7.5 MolMed Latest Developments
11.8 FUJIFILM Diosynth Biotechnologies
11.8.1 FUJIFILM Diosynth Biotechnologies Company Information
11.8.2 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Offered
11.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.8.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.9 UniQure
11.9.1 UniQure Company Information
11.9.2 UniQure Viral Vector and Plasmid DNA Product Offered
11.9.3 UniQure Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 UniQure Main Business Overview
11.9.5 UniQure Latest Developments
11.10 Aldevron
11.10.1 Aldevron Company Information
11.10.2 Aldevron Viral Vector and Plasmid DNA Product Offered
11.10.3 Aldevron Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Aldevron Main Business Overview
11.10.5 Aldevron Latest Developments
11.11 Richter-Helm
11.11.1 Richter-Helm Company Information
11.11.2 Richter-Helm Viral Vector and Plasmid DNA Product Offered
11.11.3 Richter-Helm Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Richter-Helm Main Business Overview
11.11.5 Richter-Helm Latest Developments
11.12 Eurogentec
11.12.1 Eurogentec Company Information
11.12.2 Eurogentec Viral Vector and Plasmid DNA Product Offered
11.12.3 Eurogentec Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Eurogentec Main Business Overview
11.12.5 Eurogentec Latest Developments
11.13 OBiO Technology
11.13.1 OBiO Technology Company Information
11.13.2 OBiO Technology Viral Vector and Plasmid DNA Product Offered
11.13.3 OBiO Technology Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 OBiO Technology Main Business Overview
11.13.5 OBiO Technology Latest Developments
11.14 Yposkesi
11.14.1 Yposkesi Company Information
11.14.2 Yposkesi Viral Vector and Plasmid DNA Product Offered
11.14.3 Yposkesi Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Yposkesi Main Business Overview
11.14.5 Yposkesi Latest Developments
11.15 Cell and Gene Therapy Catapult
11.15.1 Cell and Gene Therapy Catapult Company Information
11.15.2 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Offered
11.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Cell and Gene Therapy Catapult Main Business Overview
11.15.5 Cell and Gene Therapy Catapult Latest Developments
11.16 MassBiologics
11.16.1 MassBiologics Company Information
11.16.2 MassBiologics Viral Vector and Plasmid DNA Product Offered
11.16.3 MassBiologics Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 MassBiologics Main Business Overview
11.16.5 MassBiologics Latest Developments
11.17 Biovian
11.17.1 Biovian Company Information
11.17.2 Biovian Viral Vector and Plasmid DNA Product Offered
11.17.3 Biovian Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Biovian Main Business Overview
11.17.5 Biovian Latest Developments
11.18 VGXI
11.18.1 VGXI Company Information
11.18.2 VGXI Viral Vector and Plasmid DNA Product Offered
11.18.3 VGXI Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 VGXI Main Business Overview
11.18.5 VGXI Latest Developments
11.19 Gene Synthesis
11.19.1 Gene Synthesis Company Information
11.19.2 Gene Synthesis Viral Vector and Plasmid DNA Product Offered
11.19.3 Gene Synthesis Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Gene Synthesis Main Business Overview
11.19.5 Gene Synthesis Latest Developments
11.20 PlasmidFactory
11.20.1 PlasmidFactory Company Information
11.20.2 PlasmidFactory Viral Vector and Plasmid DNA Product Offered
11.20.3 PlasmidFactory Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 PlasmidFactory Main Business Overview
11.20.5 PlasmidFactory Latest Developments
11.21 Jikai Gene
11.21.1 Jikai Gene Company Information
11.21.2 Jikai Gene Viral Vector and Plasmid DNA Product Offered
11.21.3 Jikai Gene Viral Vector and Plasmid DNA Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Jikai Gene Main Business Overview
11.21.5 Jikai Gene Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
